Tango Therapeutics Q2 2024 net loss $25.6M; cash $322M, runway to 2027

Tango Therapeutics, Inc.

2024-Q2 EPS reported -$0.58 revenue$26,346,000

Net loss $25.6M ($0.24/share) vs $20.7M loss ($0.23/share) in Q2 2023.
Collaboration revenue $7.8M, down from $9.6M YoY; license revenue $12.1M (incl. $12M Gilead fee).
R&D expenses $38.7M, up from $28.7M YoY due to clinical program advancement.
Cash, equivalents and marketable securities $322.1M; expected to fund operations into 2027.
PRMT5 program (TNG908/TNG462) dose expansion ongoing; comprehensive data update expected 2H 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.